Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try

This article was originally published in The Pink Sheet Daily

Executive Summary

CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.

You may also be interested in...



Echoing Pfizer, OSI To Put IGF-1R Candidate In Phase III

Company plans to piggyback the potential lung-cancer drug – combined with Tarceva – on current Phase I study, as investors await SATURN and ATLAS details at ASCO.

Echoing Pfizer, OSI To Put IGF-1R Candidate In Phase III

Company plans to piggyback the potential lung-cancer drug – combined with Tarceva – on current Phase I study, as investors await SATURN and ATLAS details at ASCO.

As Pfizer Faces Brand Drug Challenges, Management Pushes Cost Cuts

Executives head off questions about dramatic transformational changes during third quarter earnings call; Fablyn is delayed three months by FDA.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel